 T-Lymphocytes
"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 11 | 8 | 19 | | 1997 | 20 | 5 | 25 | | 1998 | 21 | 8 | 29 | | 1999 | 18 | 6 | 24 | | 2000 | 22 | 7 | 29 | | 2001 | 22 | 9 | 31 | | 2002 | 20 | 13 | 33 | | 2003 | 20 | 11 | 31 | | 2004 | 23 | 15 | 38 | | 2005 | 28 | 8 | 36 | | 2006 | 21 | 15 | 36 | | 2007 | 17 | 10 | 27 | | 2008 | 18 | 16 | 34 | | 2009 | 23 | 14 | 37 | | 2010 | 16 | 15 | 31 | | 2011 | 11 | 21 | 32 | | 2012 | 15 | 12 | 27 | | 2013 | 33 | 15 | 48 | | 2014 | 21 | 12 | 33 | | 2015 | 21 | 14 | 35 | | 2016 | 20 | 7 | 27 | | 2017 | 19 | 16 | 35 | | 2018 | 23 | 27 | 50 | | 2019 | 24 | 24 | 48 | | 2020 | 25 | 23 | 48 | | 2021 | 23 | 28 | 51 | | 2022 | 10 | 21 | 31 | | 2023 | 4 | 27 | 31 | | 2024 | 12 | 26 | 38 | | 2025 | 23 | 5 | 28 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horiz. 2026 Jan 05; 11(1):22-36.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Landry LG, Wells KL, Anderson AM, Miller KR, Jones KL, Michels AW, Nakayama M. Quantitative V gene-targeted T cell receptor sequencing as a biomarker in type 1 diabetes. JCI Insight. 2026 Feb 09; 11(3).
-
Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI. International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025 Dec 09; 9(23):6047-6058.
-
Huey LM, Rosenzweig HL, Napier RJ. Resolving the field: a role for Nod2 in T cells. J Immunol. 2025 Dec 01; 214(12):3188-3198.
-
Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones D, Hall S, Cruz JC, Verneris MR. Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence. Blood. 2025 Nov 27; 146(22):2656-2669.
-
Gupta K, Falta NA, Spencer LA. Innate Immune Pairing: Eosinophils as Hidden Architects of T Cell Immunity. Cells. 2025 Nov 20; 14(22).
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
-
Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A. 2025 Nov 11; 122(45):e2409564122.
-
Jenkins BJ, Jenkins YR, Ponce-Garcia FM, Moscrop C, Perry IA, Hitchings MD, Uribe AH, Bernuzzi F, Eastham S, Cronin JG, Berisha A, Howell A, Davies J, Blagih J, Williams M, Marsden M, Veale DJ, Davies LC, Niphakis M, Finlay DK, Sinclair LV, Cravatt BF, Hogan AE, Nathan JA, Humphreys IR, Fearon U, Sumpton D, Vande Voorde J, Vale GDD, McDonald JG, Jones GW, Pearson JA, Vincent EE, Jones N. Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function. Nat Commun. 2025 Nov 03; 16(1):9484.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|